Infection Risks Linked to Combined Cancer Therapies
A new study reveals increased infection rates for patients receiving multiagent immunosuppressive therapies.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Should patients taking multiple immunosuppressive therapies undergo more rigorous infection screening and monitoring?
Researchers identified significant infection risks for patients treated with immune checkpoint inhibitors combined with multiagent immunosuppressive therapies. Nearly half of the infections recorded in the study were classified as severe, life-threatening, or fatal.
Why it matters
Understanding these infection patterns is critical for improving patient safety in complex cancer treatment regimens. The findings highlight specific risk factors that may necessitate more rigorous screening and preventative care for vulnerable patients.
A study of 20,930 patients analyzed 24,192 immune checkpoint inhibitor regimens administered over 13 years. Findings show age older than 65 correlates to a hazard ratio of 3.61 for opportunistic infections, while cardiac side effects link to a 3.46 ratio for nonopportunistic cases.
The players
Mass General Brigham Cancer Institute
This Boston-based research institution served as the site for the lead researchers conducting the retrospective study.
The details
The study defined multiagent immunosuppressive therapy as the administration of at least one supraphysiologic-dose corticosteroid and two steroid-sparing immunosuppressive therapies within 90 days. Of the 142 patients receiving this combination, 74 experienced a total of 152 infections, with 71 cases categorized as severe.
Timeline
The study analyzed immune checkpoint inhibitor regimens between June 2011 and February 2024.
The findings were published on September 24, 2026.
Health Landscape
This research updates clinical understandings within the Mass General Brigham Cancer Institute by identifying specific infection hazards associated with multiagent treatment combinations. It marks a significant shift in evaluating the safety profiles of combined cancer therapies for elderly and high-risk patients.
Patients undergoing intensive immunosuppressive therapy should consult their healthcare team about elevated infection risks and potential preventative screening. The findings underscore the importance of monitoring cardiac health and age-related vulnerabilities during complex cancer treatment regimens.
The takeaway
Clinicians must balance the efficacy of combined therapies against the documented risks of severe infection in high-risk groups. Patients should remain vigilant about new symptoms and communicate them immediately to their oncology providers to ensure timely intervention.
Further reading
For more information on current treatment safety research, visit the Cancer section.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Should patients taking multiple immunosuppressive therapies undergo more rigorous infection screening and monitoring?
